A citation-based method for searching scientific literature

Prashant Nasa, Sandeep Chaudhary, Pavan Kumar Shrivastava, Aanchal Singh. World J Diabetes 2021
Times Cited: 4







List of co-cited articles
7 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
786
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
986
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Euglycemic ketoacidosis induced by therapeutic fasting in a non-diabetic patient.
Alice Larroumet, Marion Camoin, Ninon Foussard, Laure Alexandre, Samir Mesli, Isabelle Redonnet, Laurence Baillet-Blanco, Vincent Rigalleau, Kamel Mohammedi. Nutrition 2020
5
25

Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association.
Abbas E Kitabchi, Guillermo E Umpierrez, Mary Beth Murphy, Robert A Kreisberg. Diabetes Care 2006
239
25


A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed.
Samantha Steinmetz-Wood, Matthew Gilbert, Katherine Menson. Case Rep Endocrinol 2020
7
25

Lactic acidosis in diabetic ketoacidosis.
Rieneke A Feenstra, Mink K P Kiewiet, E Christiaan Boerma, Ewoud ter Avest. BMJ Case Rep 2014
9
25

Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications.
Amit Bardia, Mabel Wai, Manuel L Fontes. Curr Opin Anaesthesiol 2019
15
25

Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
Venkatesan Thiruvenkatarajan, Emily Jane Meyer, Nagesh Nanjappa, Roelof M Van Wijk, David Jesudason. Br J Anaesth 2019
35
25

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Clare Arnott, Yuli Huang, Brendon L Neuen, Gian Luca Di Tanna, Christopher P Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic,[...]. Diabetes Obes Metab 2020
9
25

Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
Tamique Mason, Otavio R Coelho-Filho, Subodh Verma, Biswajit Chowdhury, Fei Zuo, Adrian Quan, Kevin E Thorpe, Christopher Bonneau, Hwee Teoh, Richard E Gilbert,[...]. JACC Cardiovasc Imaging 2021
16
25

Sodium-glucose cotransporter 2 inhibitors as the first universal treatment of chronic kidney disease.
Usama Abdel Azim Sharaf El Din, Mona Mansour Salem, Dina Ossama Abdulazim. Nefrologia (Engl Ed) 2021
1
100

Disruption of energy utilization in diabetic cardiomyopathy; a mini review.
Shinsuke Nirengi, Carmem Peres Valgas da Silva, Kristin I Stanford. Curr Opin Pharmacol 2020
6
25

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
315
25

Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Kirsten Thiele, Matthias Rau, Niels-Ulrik K Hartmann, Julia Möllmann, Joachim Jankowski, Michael Böhm, András P Keszei, Nikolaus Marx, Michael Lehrke. Diabetes Obes Metab 2021
3
33


Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension.
Giovanna Castoldi, Raffaella Carletti, Silvia Ippolito, Massimiliano Colzani, Francesca Barzaghi, Andrea Stella, Gianpaolo Zerbini, Gianluca Perseghin, Cira R T di Gioia. Am J Nephrol 2020
15
25

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes.
Jens Aberle, Markus Menzen, Sebastian M Schmid, Christoph Terkamp, Elmar Jaeckel, Katja Rohwedder, Markus F Scheerer, John Xu, Weifeng Tang, Andreas L Birkenfeld. Sci Rep 2020
7
25

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Glenn M Chertow, Priya Vart, Niels Jongs, Robert D Toto, Jose Luis Gorriz, Fan Fan Hou, John J V McMurray, Ricardo Correa-Rotter, Peter Rossing, C David Sjöström,[...]. J Am Soc Nephrol 2021
15
25

Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin, Michael W Fong,[...]. Diabetes Obes Metab 2021
7
25

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Paola Fioretto, Stefano Del Prato, John B Buse, Ronald Goldenberg, Francesco Giorgino, Daniel Reyner, Anna Maria Langkilde, C David Sjöström, Peter Sartipy. Diabetes Obes Metab 2018
73
25

Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.
Yake Lou, Ying Yu, Junchao Duan, Sining Bi, Khaing Nyein Chan Swe, Ziwei Xi, Yanan Gao, Yujie Zhou, Xiaomin Nie, Wei Liu. Ther Adv Chronic Dis 2020
4
25

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
Eva M Boorsma, Joost C Beusekamp, Jozine M Ter Maaten, Sylwia M Figarska, A H Jan Danser, Dirk J van Veldhuisen, Peter van der Meer, Hiddo J L Heerspink, Kevin Damman, Adriaan A Voors. Eur J Heart Fail 2021
20
25

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
767
25

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.
Alessandro Mantovani, Alessandro Csermely, Graziana Petracca, Giorgia Beatrice, Kathleen E Corey, Tracey G Simon, Christopher D Byrne, Giovanni Targher. Lancet Gastroenterol Hepatol 2021
18
25

Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials.
Robert D Toto, Ronald Goldenberg, Glenn M Chertow, Valerie Cain, Bergur V Stefánsson, C David Sjöström, Peter Sartipy. J Diabetes Complications 2019
13
25

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.
R Chilton, I Tikkanen, C P Cannon, S Crowe, H J Woerle, U C Broedl, O E Johansen. Diabetes Obes Metab 2015
265
25

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Mikhail Kosiborod, Carolyn S P Lam, Shun Kohsaka, Dae Jung Kim, Avraham Karasik, Jonathan Shaw, Navdeep Tangri, Su-Yen Goh, Marcus Thuresson, Hungta Chen,[...]. J Am Coll Cardiol 2018
250
25

Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
Anne Zanchi, Michel Burnier, Marie-Eve Muller, Arlène Ghajarzadeh-Wurzner, Marc Maillard, Nicolas Loncle, Bastien Milani, Nathalie Dufour, Olivier Bonny, Menno Pruijm. J Am Heart Assoc 2020
21
25

Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study.
Juan Antonio Requena-Ibáñez, Carlos G Santos-Gallego, Anderly Rodriguez-Cordero, Ariana P Vargas-Delgado, Donna Mancini, Samantha Sartori, Farah Atallah-Lajam, Chiara Giannarelli, Frank Macaluso, Anuradha Lala,[...]. JACC Heart Fail 2021
20
25


Double product reflects the predictive power of systolic pressure in the general population: evidence from 9,937 participants.
Rudolph Schutte, Lutgarde Thijs, Kei Asayama, José Boggia, Yan Li, Tine W Hansen, Yan-Ping Liu, Masahiro Kikuya, Kristina Björklund-Bodegård, Takayoshi Ohkubo,[...]. Am J Hypertens 2013
22
25

SGLT2 inhibitors: β blockers for the kidney?
Richard E Gilbert. Lancet Diabetes Endocrinol 2016
28
25


SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee,[...]. Nat Commun 2020
89
25


Renin-angiotensin system: Basic and clinical aspects-A general perspective.
Rafael Antonio Vargas Vargas, Jesús María Varela Millán, Esperanza Fajardo Bonilla. Endocrinol Diabetes Nutr 2022
2
50

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
228
25

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Paul K Whelton, Robert M Carey, Wilbert S Aronow, Donald E Casey, Karen J Collins, Cheryl Dennison Himmelfarb, Sondra M DePalma, Samuel Gidding, Kenneth A Jamerson, Daniel W Jones,[...]. Hypertension 2018
25

Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial.
Jesper Jensen, Massar Omar, Caroline Kistorp, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Jens Faber, Mariam Elmegaard Malik, Emil Loldrup Fosbøl,[...]. Lancet Diabetes Endocrinol 2021
32
25

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice.
Jan Pennig, Philipp Scherrer, Mark Colin Gissler, Nathaly Anto-Michel, Natalie Hoppe, Lisa Füner, Carmen Härdtner, Peter Stachon, Dennis Wolf, Ingo Hilgendorf,[...]. Sci Rep 2019
20
25

Effects of intensive exercise combined with dapagliflozin on body composition in patients with type 2 diabetes: a randomized controlled trial.
Ryotaro Bouchi, Noriyuki Sonoda, Jun Itoh, Yasuhiro Ono, Tatsuya Fukuda, Takato Takeuchi, Junji Kishimoto, Tetsuya Yamada, Yoshihiro Ogawa. Endocr J 2021
3
33

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
656
25

2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Paul K Whelton, Robert M Carey, Wilbert S Aronow, Donald E Casey, Karen J Collins, Cheryl Dennison Himmelfarb, Sondra M DePalma, Samuel Gidding, Kenneth A Jamerson, Daniel W Jones,[...]. Hypertension 2018
25

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial.
Mikkel Jürgens, Morten Schou, Philip Hasbak, Andreas Kjær, Emil Wolsk, Bo Zerahn, Mikkel Wiberg, Niels H Brandt-Jacobsen, Peter Gæde, Peter Rossing,[...]. J Am Heart Assoc 2021
4
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.